
    
      This study is a prospective biomarker study of patients with mCRPC undergoing treatment with
      radium-223 as standard of care treatment. The participants will undergo serial pre- and
      post-therapy blood collection for biomarker analysis as part of the primary objective of the
      study.
    
  